AGREEMENTRegistration Rights Agreement • April 13th, 2004 • Adventrx Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
NO. WA2-64 ISSUED: APRIL 19, 2004 A-2 WARRANT TO PURCHASE COMMON STOCK THIS CERTIFIES THAT, for good and valuable consideration, Franklin M. Berger (the "HOLDER") is entitled to purchase from Adventrx Pharmaceuticals, Inc., a Delaware corporation (the...Warrant Agreement • May 12th, 2004 • Adventrx Pharmaceuticals Inc • Pharmaceutical preparations • California
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 30th, 2009 • Adventrx Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of June 29, 2009, between ADVENTRX Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
Exhibit 4.23 SECURITIES PURCHASE AGREEMENT dated as of July 21, 2005,Securities Purchase Agreement • August 12th, 2005 • Adventrx Pharmaceuticals Inc • Pharmaceutical preparations • New York
EXHIBIT 4.29 THIS WARRANT HAS BEEN, AND THE SHARES OF COMMON STOCK WHICH MAY BE RECEIVED PURSUANT TO THE EXERCISE OF THIS WARRANT WILL BE, ACQUIRED SOLELY FOR INVESTMENT AND NOT WITH A VIEW TO, OR FOR RESALE IN CONNECTION WITH, ANY DISTRIBUTION...Warrant Agreement • September 2nd, 2005 • Adventrx Pharmaceuticals Inc • Pharmaceutical preparations • California
Exhibit 10.6 EXECUTIVE EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT, made as of the 1st day of December, 1999, by and between Warren C. Lau (the "Executive"), an individual residing 16702 Tennison Court, Spring, Texas, 77379 and BioQuest, Inc. (the...Executive Employment Agreement • October 2nd, 2001 • Biokeys Pharmaceuticals Inc • Delaware
EXHIBIT 4.27 THIS WARRANT HAS BEEN, AND THE SHARES OF COMMON STOCK WHICH MAY BE RECEIVED PURSUANT TO THE EXERCISE OF THIS WARRANT WILL BE, ACQUIRED SOLELY FOR INVESTMENT AND NOT WITH A VIEW TO, OR FOR RESALE IN CONNECTION WITH, ANY DISTRIBUTION...Warrant Agreement • September 2nd, 2005 • Adventrx Pharmaceuticals Inc • Pharmaceutical preparations • California
BACKGROUNDRegistration Rights Agreement • June 30th, 2004 • Adventrx Pharmaceuticals Inc • Pharmaceutical preparations • California
MAST THERAPEUTICS, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SUBORDINATED DEBT SECURITIESIndenture • March 24th, 2015 • Mast Therapeutics, Inc. • Pharmaceutical preparations • New York
INDENTURE, dated as of [—], 20[—], among MAST THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [TRUSTEE], as trustee (the “Trustee”):
26,246,720 Shares of Common Stock Savara Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • June 28th, 2024 • Savara Inc • Pharmaceutical preparations • New York
NO. WA1- ISSUED: APRIL 8, 2004 A-1 WARRANT TO PURCHASE COMMON STOCK THIS CERTIFIES THAT, for good and valuable consideration, ___________ (the "HOLDER") is entitled to purchase from Adventrx Pharmaceuticals, Inc., a Delaware corporation (the...Warrant Agreement • May 12th, 2004 • Adventrx Pharmaceuticals Inc • Pharmaceutical preparations • California
SAVARA INC. SHARES OF COMMON STOCK (PAR VALUE $0.001 PER SHARE) SALES AGREEMENTSales Agreement • July 6th, 2021 • Savara Inc • Pharmaceutical preparations • New York
SAVARA INC., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with EVERCORE GROUP L.L.C. (the “Agent”) as follows:
RECITALSRegistration Rights Agreement • September 15th, 2004 • Adventrx Pharmaceuticals Inc • Pharmaceutical preparations • New York
EXHIBIT 4.21 THIS WARRANT HAS BEEN, AND THE SHARES OF COMMON STOCK WHICH MAY BE RECEIVED PURSUANT TO THE EXERCISE OF THIS WARRANT WILL BE, ACQUIRED SOLELY FOR INVESTMENT AND NOT WITH A VIEW TO, OR FOR RESALE IN CONNECTION WITH, ANY DISTRIBUTION...Warrant Agreement • June 30th, 2004 • Adventrx Pharmaceuticals Inc • Pharmaceutical preparations • California
BACKGROUNDRights Agreement • August 12th, 2005 • Adventrx Pharmaceuticals Inc • Pharmaceutical preparations • New York
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • May 3rd, 2010 • Adventrx Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of May 2, 2010, between ADVENTRX Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
MAST THERAPEUTICS, INC. SALES AGREEMENTSales Agreement • August 21st, 2015 • Mast Therapeutics, Inc. • Pharmaceutical preparations • New York
Mast Therapeutics, Inc. (the “Company”) confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as set forth below. This Agreement shall terminate and supersede that certain Sales Agreement, dated February 10, 2014, by and between the Company and Cowen (the “Prior Agreement”) as of the effective date of this Agreement and, upon entry into this Agreement, no further sales shall be made pursuant to the Prior Agreement.
21,250,000 SHARES of Common Stock and 10,625,000 WARRANTS OF ADVENTRX PHARMACEUTICALS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • November 14th, 2011 • Adventrx Pharmaceuticals Inc • Pharmaceutical preparations • New York
The undersigned, ADVENTRX Pharmaceuticals, Inc., a company formed under the laws of Delaware (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement as being subsidiaries or affiliates of the Company, the “Company”), hereby confirms its agreement (this “Agreement”) with the several underwriters (such underwriters, including the Representative (as defined below), the “Underwriters”) named in Schedule I hereto for whom Rodman & Renshaw, LLC is acting as representative (the “Representative” and if there are no Underwriters other than the Representative, references to multiple Underwriters shall be disregarded and the term Representative as used herein shall have the same meaning as Underwriter) on the terms and conditions set forth herein.
EXHIBIT 4.20 STOCK SUBSCRIPTION AGREEMENT ADVENTRX Pharmaceuticals, Inc. 9948 Hibert Street, Suite 100 San Diego, CA 92131 This letter represents an agreement (this "AGREEMENT") between the undersigned (the "INVESTOR") and ADVENTRX Pharmaceuticals,...Stock Subscription Agreement • June 30th, 2004 • Adventrx Pharmaceuticals Inc • Pharmaceutical preparations • California
FIRST AMENDMENT TO LICENSE AGREEMENTLicense Agreement • October 2nd, 2001 • Biokeys Pharmaceuticals Inc
COMMON STOCK PURCHASE WARRANT ADVENTRX PHARMACEUTICALS, INC.Security Agreement • November 14th, 2011 • Adventrx Pharmaceuticals Inc • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (this “Warrant”) certifies that, for value received, , or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Initial Exercise Date, as listed above, and on or prior to the close of business on April 1, 2015 (the “Termination Date”) but not thereafter, to subscribe for and purchase from ADVENTRX Pharmaceuticals, Inc., a Delaware corporation (the “Company”), up to shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s common stock (“Common Stock”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is issued by the Company as of the date hereof pursuant to (i) Section A.2 of the Engagement Letter Agreement, dated May 17, 2011, between the Company and Rodman & Renshaw, LLC and (ii) Section 4(2) of the Securities Act an
BY AND AMONGMerger Agreement • October 2nd, 2001 • Biokeys Pharmaceuticals Inc • Delaware
50,000,000 Units Each Unit Consisting of One Share of Common Stock And One Warrant to Purchase 0.5 of a Share of Common Stock Mast Therapeutics, Inc. PURCHASE AGREEMENTPurchase Agreement • June 17th, 2013 • Mast Therapeutics, Inc. • Pharmaceutical preparations • New York
Mast Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 50,000,000 units (the “Firm Units”), each of which shall consist of (i) one (1) share of the Company’s Common Stock, $0.001 par value per share (the “Common Stock”) (such shares of Common Stock constituting a part of the Units, collectively the “Shares”), and (ii) one warrant to purchase 0.5 of a share of Common Stock (such warrants constituting a part of the Units, collectively the “Warrants”). The Company has also granted to the Underwriters an option to purchase up to 7,500,000 additional units on the terms and for the purposes set forth in Section 3 hereof (the “Option Units”). The shares of Common Stock issuable upon exercise of the Warrants are called the “Warrant Shares,” and the Warrant Shares, together with the Warrants and the Shares, are called the “Securities.” The Firm Units and any Option Units purcha
COMMON STOCK AND WARRANT PURCHASE AGREEMENT This Common Stock and Warrant Purchase Agreement (this "AGREEMENT"), dated as of April 5, 2004 (the "AGREEMENT DATE"), is among ADVENTRX Pharmaceuticals, Inc., a Delaware corporation (the "COMPANY"), and...Common Stock and Warrant Purchase Agreement • June 30th, 2004 • Adventrx Pharmaceuticals Inc • Pharmaceutical preparations • California
STRICTLY CONFIDENTIAL Mr. Brian M. Culley Chief Executive Officer Adventrx Pharmaceuticals Inc. 6725 Mesa Ridge Road Suite 100 San Diego, CA 92121 Dear Mr. Culley:Placement Agent Agreement • January 7th, 2011 • Adventrx Pharmaceuticals Inc • Pharmaceutical preparations • New York
This letter (this “Agreement”) constitutes the agreement between Adventrx Pharmaceuticals Inc. (the “Company”) and Rodman & Renshaw, LLC (“Rodman” or the “Placement Agent”) that Rodman shall serve as the exclusive (i) placement agent for the Company (“Direct Placement”) on a reasonable best efforts basis or (ii) underwriter for the Company, on a firm commitment basis (“Underwritten Placement”), in connection with the proposed reasonable best efforts placement or series of placements to occur during the term of this Agreement (the “Placement”). The Placement shall consist of registered or unregistered securities (the “Securities”) of the Company, which Securities may include one or any combination of the following: shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), warrants to purchase shares of Common Stock (“Warrants”) or securities of the Company convertible into shares of Common Stock of the Company “Convertible Securities”). The terms of such Pla
SERIES A/B] COMMON STOCK PURCHASE WARRANT ADVENTRX PHARMACEUTICALS, INC.Common Stock Purchase Warrant • January 7th, 2011 • Adventrx Pharmaceuticals Inc • Pharmaceutical preparations
THIS [SERIES A/B] COMMON STOCK PURCHASE WARRANT (this “Warrant”) certifies that, for value received, _____________ (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Initial Exercise Date (as defined above) and on or prior to the close of business on ________1 (the “Termination Date”) but not thereafter, to subscribe for and purchase from ADVENTRX Pharmaceuticals, Inc., a Delaware corporation (the “Company”), up to ______ shares (the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
EXHIBIT 4.33 THIS WARRANT HAS BEEN, AND THE SHARES OF COMMON STOCK WHICH MAY BE RECEIVED PURSUANT TO THE EXERCISE OF THIS WARRANT WILL BE, ACQUIRED SOLELY FOR INVESTMENT AND NOT WITH A VIEW TO, OR FOR RESALE IN CONNECTION WITH, ANY DISTRIBUTION...Warrant Agreement • August 26th, 2005 • Adventrx Pharmaceuticals Inc • Pharmaceutical preparations • California
29,090,910 UNITS, EACH UNIT CONSISTING OF ONE SHARE OF COMMON STOCK AND ONE WARRANT TO PURCHASE ONE SHARE OF COMMON STOCK, OF MAST THERAPEUTICS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • February 11th, 2016 • Mast Therapeutics, Inc. • Pharmaceutical preparations • New York
The undersigned, Mast Therapeutics, Inc., a company incorporated under the laws of the State of Delaware (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement as being subsidiaries or affiliates of Mast Therapeutics, Inc. (the “Company”)), hereby confirms its agreement (this “Agreement”) with the several underwriters (such underwriters, including the Representative (as defined below), the “Underwriters” and, each, an “Underwriter”) named in Schedule I hereto for which Roth Capital Partners, LLC is acting as representative to the several Underwriters (the “Representative” and if there are no Underwriters other than the Representative, references to multiple Underwriters shall be disregarded and the term Representative as used herein shall have the same meaning as Underwriter) on the terms and conditions set forth herein.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • January 7th, 2011 • Adventrx Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of January 6, 2011, between ADVENTRX Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
AGREEMENTRegistration Rights Agreement • May 12th, 2004 • Adventrx Pharmaceuticals Inc • Pharmaceutical preparations • California
RECITALSPatent and Technology License Agreement • January 14th, 2002 • Biokeys Pharmaceuticals Inc • Pharmaceutical preparations • Texas
INDEMNIFICATION AGREEMENTIndemnification Agreement • October 23rd, 2006 • Adventrx Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
This Agreement is made as of , 2006, between ADVENTRX Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and (the “Indemnitee”).
Exhibit 1 BIOKEYS PHARMACEUTICALS, INC. SERIES C CONVERTIBLE PREFERRED STOCK PURCHASE AGREEMENT This SERIES C CONVERTIBLE PREFERRED STOCK PURCHASE AGREEMENT (this "AGREEMENT") is dated as of the 27th day of September, 2002 by and among Biokeys...Series C Convertible Preferred Stock Purchase Agreement • October 21st, 2002 • Biokeys Pharmaceuticals Inc • Pharmaceutical preparations • California
AGREEMENTRegistration Rights Agreement • April 13th, 2004 • Adventrx Pharmaceuticals Inc • Pharmaceutical preparations • California
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • January 4th, 2010 • Adventrx Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of January 4, 2010, between ADVENTRX Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
